DT
CTMX icon

Diversified Trust’s CytomX Therapeutics CTMX Stock Holding History

Diversified Trust’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,582
Closed -$67K – 807
2021
Q2 		$67K Sell
10,582
-5,607
-35% -$43.7K ﹤0.01% 769
2021
Q1 		$125K Buy
+16,189
New +$128K ﹤0.01% 722
2020
Q4 		– Sell
-13,651
Closed -$91K – 747
2020
Q3 		$91K Buy
13,651
+3,051
+29% +$22.6K ﹤0.01% 616
2020
Q2 		$88K Buy
+10,600
New +$98.4K ﹤0.01% 533

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Diversified Trust's CTMX Position: Q3 2021 in Review

Diversified Trust sold out of CytomX Therapeutics (CTMX) in Q3 2021, closing a stake of 10,582 shares — an estimated $67K sold.

Diversified Trust first reported a position in CTMX in Q2 2020 and held it in 4 quarters. The position peaked at $125K in Q1 2021. 114 funds tracked by Wall St. Rank hold CTMX as of Q3 2021.

  • Diversified Trust reported no remaining CytomX Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Diversified Trust sold 10,582 CytomX Therapeutics shares in Q3 2021, an estimated $67K.
  • Diversified Trust first reported a position in CytomX Therapeutics in Q2 2020 and held it in 4 quarters.
  • Diversified Trust's CytomX Therapeutics position peaked at $125K in Q1 2021.
  • 114 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2021.

Based on Diversified Trust's 13F filing for Q3 2021, filed 13 Jan 2022.